These results may provide a theoretical basis for the use of ICIs and ICIs combined with chemotherapy and anti‐angiogenesis in EGFR‐mutated NSCLC patients after EGFR‐TKI treatment failure. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.